Specializing in Natural Hormone Replacement for men and women.
Evidence Based Hormone Therapy Bibliography
  1. Bioienticals:Sorting Myths from Facts. Available at http://www.fda.gov/consumer/updates/bioidenticals040808.pdf
  2. The Endocrine Society. Bioidentical Hormones Position Statement, October 2006. http://www.endosociety. org/publicpolicy/policy/policy/upload/BH_Position_Statement_final_10_
    25_06_w_Header/pdf. Accessed. December 30, 2008.
  3. ACOG on BHRTACOG, Compounded Bioidentical Hormones, AGOG Committee Op. No. 322, 106 Obstet Gynecol 2005, 1139, 1140 (Nov. 2005)
  4. No Scientific Evidence Supporting Effectiveness or Safety of Compounded Bioidentical Hormone Therapy (Oct. 31, 2005), available at http://www.acog.org/from_home/publications/press_releases/nr10-31-05-1.cfm.
  5. AMA, FDA Oversight of Bioidentical Hormone (BH) Preparations, Res. 706,
    at 1, available at http://www. ama-assn.org/ama1/pub/upload/mm/475/706.doc     (last visited Apr. 3, 2007)
  6. NAMS, Estrogen and Progestogen Use in Peri- and Postmenopausal Women: March 2007 Position Statement of The North American Menopause Society, 14 Menopause: J. of The N. Am. Menopause Soc’y 168, 174, available at http://www.menopause.org/PSHT07.pdf.
  7. FDA Science and Mission Report: A confidential report of the Subcommittee on Science and Technology prepared for the FDA Science Board.
    Available at http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007- 4329b_02_01_FDA%20Report%20on%20Science%20and%20
    Technology.pdf accessed Jan 9 2009.
  8. Mueck AO, Seeger H, Wallwiener D. Comparison of proliferative effects of estradiol and conjugated equine estrogens on human breast cancer cells and impact of continuous combined progestogen addition. Climacteric. 2003;6(3):221–227.
  9. Magnusson C, Baron JA, Correia N, Bergström R, Adami HO, Persson I. Breast-cancer risk following long-term oestrogen- and oestrogen/progestin-replacement therapy. Int J Cancer. 1999;81(3):339–344.
  10. Chen WY, Manson JE, Hankinson SE, Rosner B, Holmes MD, Willett WC, Colditz GA (2006). Unopposed estrogen therapy and the risk of invasive breast cancer. Arch Intern Med. 2006; 166(9):1027-32.
  11. Beral V, Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003 Aug 9;362(9382):419-27
  12. Bakken K, Alsaker E, Eggen AE, Lund E. Hormone replacement therapy and incidence of hormone-dependent cancers in the Norwegian Women and Cancer study. Int J Cancer. 2004;112(1):130–134.
  13. Ripot C,Tremollieres F. Hormone replacement therapy in postmenopausal women. All the treatments are not the same. Gynecol Obstet Fertil 2007; 35:1-10.
  14. Mueck A, Seeger H, Wallweiner D. Comparison of the proliferative effects of estradiol and conjugated estrogens on human breast cancer cells and the impact of continuous combined progestogen addition. Climacteric 2003:6:221-227.
  15. Isaksson E, Wang H, Sahlin L, et al. Expression of estrogen receptors (alpha, beta) and insulin-like growth factor-1 in breast tissue form surgically postmenopausal cynomolgus macaques after long-term treatment with HRT and tamoxifen. Breast. 2002;11(4):295–300.
  16. Pisha E, Lui X, Constantinou AI, Bolton JL. Evidence that a metabolite of equine estrogens, 4-hydroxequilenin, induces cellular transformation in vitro. Chem Res Toxicol. 2001;14(1):82–90.
  17. Zhang F, Chen Y, Pisha E, et al. The major metabolite of equilin, 4-hyroxyequilin, autoxidizes to an o-quinone with isomerizes to the potent cytotoxin 4-hydroyequilenin-o-quinone. Chem Res Toxicol. 1999;12(2):204–213.
  18. Chen Y, Liu X, Pisha E, et al. A metabolite of equine estrogens, 4-hydroxyequilenin, induces DNA damage and apoptosis in breast cancer cell lines. Chem Res Toxicol. 2000;13(5):342–350.
  19. Zhang F, Swanson SM, van Breemen RB, et al. Equine estrogen metabolite 4 hydroxyequilenin induces DNA damage in the rat mammary tissues: formation of single-strand breaks, apurinic sites, stable adducts, and oxidized bases. Chem Res Toxicol. 2001;14(12):1654–1659.
  20. Shen L, Qiu S, Chen Y, et al. Alkylation of 2’-deoxynucleosides and DNA by the Premarin metabolite 4-hydroxyequilenin semiquinone radical. Chem Res Toxicol. 1998;11(2):94–101.
  21. Paruthiyil S, Parma H, Kerekatte V, Cunha GR, Firestone GL, Leitman DC. Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cycle arrest. Cancer Res. 2004;64(1):423–428.
  22. Helguero LA, Faulds MH, Gustafsson JA, Haldosén LA. Estrogen receptors alpha (ERalpha) and beta (ERbeta) differentially regulate proliferation and apoptosis of the normal murine mammary epithelial cell line HC11. Oncogene. 2005;24(44):6605–6616.
  23. Bardin A, Boulle N, Lazennec G, Vignon F, Pujol P. Loss of ERbeta expression as a common step in estrogendependent tumor progression. Endocr Relat Cancer. 2004;11(3):537–551.
  24. Weatherman RV, Clegg NJ, Scanlan TS. Differential SERM activation of the estrogen receptors (ERalpha and ERbeta) at AP-1 sites. Chem Biol. 2001;8(5):427–436. 2
  25. Pettersson K, Delaunay F, Gustafsson JA. Estrogen receptor beta acts a dominant regulator of estrogen signaling. Oncogene.2000;19(43):4970–4978.
  26. Saji S, Jensen EV, Nilsson S, Rylander T, Warner, Gustafsson JA. Estrogen receptors alpha and beta in the rodent mammary gland. Proc Natl Acad Sci U S A. 2000;97(1):337–342.
  27. Zhu BT, Han GZ, Shim JY, Wen Y, Jiang XR. Quantitative structure activity relationship of various endogenous estrogen metabolites for human estrogen receptor alpha and beta subtypes: Insights into the structural determinants favoring a differential subtype binding. Endocrinology. 2006;147(9):4132–4150.
  28. Rich RL, Hoth LR, Geoghegan KF, et al. Kinetic analysis of strogen receptor/ligand interactions. Proc Natl Acad Sci U S A. 2002;99(13):8562–8567.
  29. Campagnoli C, Abba C, Ambroggio S, Peris C. Pregnancy, progesterone and progestins in relation to breast cancer risk. J Steroid Biochem Mol Biol. 2005;97(5):441–450.
  30. Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat. 2008;107(1):103–111.
  31. Innes KE, Byers TE. First pregnancy characteristics and subsequent breast cancer risk among young women. Int J Cancer. 2004;112(2):306–311.
  32. Troisi R, Weiss HA, Hoover RN, et al. Pregnancy characteristics and maternal risk of breast cancer. Epidemiology. 1998;9(6):641–647.
  33. Vatten LJ, Romundstad PR, Trichopoulos D, Skjærven R. Pre-eclampsia in pregnancy and subsequent risk for breast cancer. Br J Cancer. 2002;87(9):971–973.
  34. Lemon HM. Pathophysiologic considerations in the treatment of menopausal patients with oestrogens; the role of oestriol in the prevention of mammary carcinoma. Acta Endocrinol Suppl (Copenh). 980;233:17–27.
  35. Lemon HM, Kumar PF, Peterson C, Rodriguez-Sierra JF, Abbo KM. Inhibition of radiogenic mammary carcinomain rats by estriol or tamoxifen. Cancer. 1989;63(9):1685–1692.
  36. Lemon HM. Estriol prevention of mammary carcinoma induced by 7,12-dimethylbenzanthracene and procarbazine. Cancer Res. 1975;35(5):1341–1353.
  37. MacMahon B, Cole P, Brown JB, et al. Oestrogen profiles of Asian and North American women. Lancet. 1971;2(7730):900–902.
  38. Gross J, Modan B, Bertini B, et al. Relationship between steroid excretion patterns and breast cancer incidence in. Israeli women of various origins. J Natl Cancer Inst. 1997;59(1):7–11.
  39. Cole P, MacMahon B. Oestrogen fractions during early reproductive life in the aetiology of breast cancer. Lancet. 1969;1(7595):604–606.
  40. Dickinson LE, MacMahon B, Cole P, Brown JB. Estrogen profiles of Oriental and Caucasian women in Hawaii. N Engl J Med. 1974;291(23):1211–1213.
  41. Melamed M, Castaño E, Notides AC, Sasson S. Molecular and kinetic basis for the mixed agonist/antagonist activity of estriol. Mol Endocrinol. 1997;11(12):1868–1878.
  42. Speroff L. The breast as an endocrine target organ. Contemp Obstet Gynec. 1977;9:69–72.
  43. Rosner B, Colditz, GA, Willett WC. Reproductive risk factors in a prospective study of breast cancer: the Nurses’ Health Study. Am J Epidemiol. 1994;139(8):819–835.
  44. Russo J, Tay LK, Russo IH. Differentiation of the mammary gland and susceptibility to carcinogenesis. Breast Cancer Res Treat. 1982;2(1):5–73.
  45. Pasqualini JR. The fetus, pregnancy, and breast cancer. In: Pasqualini JR, ed. Breast Cancer: Prognosis, Treatment, and Prevention. New York, NY: Marcel Dekker Inc; 2002:19–71.
  46. Vatten LJ, Romundstad PR, Trichopoulos D, Skjærven R. Pregnancy related protection against breast cancer depends on length of gestation. Br J Cancer. 2002;87(3):289–290.
  47. Ekbom A, Hsieh CC, Lipworth L, Adami HQ, Trichopoulos D. Intrauterine environment and breast cancer risk in women: a population based study. J Natl Cancer Inst. 1997;89(1):71–76.
  48. Ursin G, Wilson M, Henderson BE, et al. Do urinary estrogen metabolites reflect the differences in breast cancer risk between Singapore Chinese and United States African-American and white women? Cancer Res. 2001;61(8):3326–3329.
  49. Lemon HM. Genetic predisposition to carcinoma of the breast: multiple human genotypes for estrogen 16 alpha hydroxylase activity in Caucasians. J Surg Oncol. 1972;4(3):255–273.
  50. Lemon HM, Wotiz HH, Parsons L, Mozden PJ. Reduced estriol excretion in patients with breast cancer prior to endocrine therapy. JAMA. 1966;196(13):1128–136.
  51. Marmorston J, Fowley LG, Myers SM, Stern E, Hopkins CE. II. Urinary excretion of estrone, estradiol and estriol by patients with breast cancer and benign breast disease. Am J Obstet Gynecol. 1965;92:460–467.
  52. Takahashi K. Efficacy and safety of oral estriol for managing postmenopausal symptoms. Maturitas 15-FEB- 2000; 34(2): 169-77
  53. Head KA – Estriol: Safety and Efficacy Altern Med Rev - 01-APR-1998; 3(2): 101-13 3
  54. Vooijs GP. Review of the endometrial safety during intravaginal treatment with estriol Eur J Obstet Gynecol Reprod Biol - 01-SEP-1995; 62(1): 101-6
  55. Takahashi K. Safety and efficacy of oestriol for symptoms of natural or surgically induced menopause.Hum Reprod - 01-MAY-2000; 15(5): 1028-36
  56. Kicovic PM. The treatment of postmenopausal vaginal atrophy with Ovestin vaginal cream or suppositories: clinical, endocrinological and safety aspects Maturitas - 01-DEC-1980; 2(4): 275-82
  57. de Lignières B. Effects of progestogens on the postmenopausal breast. Climacteric. 2002;5(3):229–235.
  58. Campagnoli C, Clavel-Chapelon F, Kaaks R, Peris C, Berrino F. Progestins and progesterone in hormone replacement therapy and the riskof breast cancer. J Steroid Biochem Mol Biol. 2005;96(2):95–108.
  59. Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer. 2005;114:448–454.
  60. Rossouw JE, Anderson GL, Prentice RL, et al; Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–333.
  61. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA. 2004;291(14):1701–1712.
  62. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women’s Health Initiative Randomized Trial. JAMA. 2003;289(24):3243–3253.
  63. Porch JV, Lee IM, Cook NR, Rexrode KM, Burin JE. Estrogen-progestin replacement therapy and breast cancer risk: the Women’s Health Study (United States). Cancer Causes Control. 2002;13(9):847–854.
  64. Lee SA, Ross RK, Pike MC. An overview of menopausal oestrogen progestin hormone therapy and breast cancer risk. Br J Cancer. 2005;92(11):2049–2058.
  65. Ewertz M, Mellemkjaer L, Poulsen AH, et al. Hormone use for menopausal symptoms and risk of breast cancer. A Danish cohort study. Br J Cancer. 2005;92(7):1293–1297.
  66. Newcomb PA, Titus-Ernstoff L, Egan KM, et al. Postmenopausal estrogen and progestin use in relation to breast cancer risk. Cancer Epid Bio Prev. 2002;11(7):593–600.
  67. Stahlberg C, Pedersen AT, Lynge E, et al. Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe. Int J Cancer. 2004;109(5):721–727.
  68. Li CI. Postmenopausal hormone therapy and the risk of breast cancer: the view of an epidemiologist. Maturitas. 2004;49(1):44–50.
  69. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Estrogen-progestin replacement and risk of breast cancer. JAMA. 2000;284(6):691–694.
  70. Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst. 2000;92(4):328–332.
  71. Warren MP. A comparative review of the risks and benefits of hormone replacement therapy regimens. Am J Obstet Gynecol. 2004;190(4):1141–1167.
  72. Weiss LK, Burkman RT, Cushing-Haugen KL, et al. Hormone replacement therapy regimens and breast cancer risk(1). Obstet Gynecol.2002;100(6):1148–1158.
  73. Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, Thijssen JH. Classification and pharmacology of progestins. Maturitas. 2003 Dec 10;46 Suppl 1:S7-S16.
  74. Stanczyk F. All progestins are not created equal. Steroids 2003;68:879-890.
  75. Li CI, Malone KE, Porter PL, et al. Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA. 2003;289(24):3254–3263.
  76. Beral V; Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003;362(9382):419–427.
  77. Kirsh V, Kreiger N. Estrogen and estrogen–progestin replacement therapy and risk of postmenopausal breast cancer in Canada. Cancer Causes Control. 2002;13(6):583–590.
  78. 78. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet. 1997;350(9084):1047–1059.
  79. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA. 2000;283(4):485–491.
  80. Colditz G, Rosner B. Use of estrogen plus progestin is associated with greater increase in breast cancer risk than estrogen alone. Am J Epidemiol. 1998;147:S45.
  81. Persson I, Weiderpass E, Bergkvist L, Bergström R, Schairer C. Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement. Cancer Causes Control. 1999;10(4):253–260.
  82. Chen CL, Weiss NS, Newcomb P, Barlow W, White E. Hormone replacement therapy in relation to breast cancer. JAMA. 2002;287(6):734–741. 4
  83. Pike MC, Ross RK. Progestins and menopause: epidemiological studies of risks of endometrial and breast cancer. Steroids. 2000;65(10–11-):659–664.
  84. Santen RJ, Pinkerton J, McCartney C, Petroni GR. Risk of breast cancer with progestins in combination with estrogen as hormone replacement therapy. J Clin Endocrinol Metab. 2001;86(1):16–23.
  85. Stahlberg C, Pederson AT, Lynge E, Ottesen B. Hormone replacement therapy and risk of breast cancer: the role of progestins. Acta Obstet Gynecol Scand. 2003;82(7):335–344.
  86. Olsson HL, Ingvar C, Bladström A. Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden. Cancer. 2003;97(6):1387–1392.
  87. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med. 1995;332(24):1589–1593.
  88. Colditz GA, Rosner B. Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses’ Health Study. Am J Epidemiol. 2000;152(10):950–964.
  89. Chang KJ, Lee TY, Linares-Cruz G, Fournier S, de Ligniéres B. Influences of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo. Fertil Steril.1995;63(4):785–791.
  90. Foidart JM, Colin C, Denoo X, et al. Estradiol and progesterone regulate the proliferation of human breast epithelial cells. Fertil Steril.1998;69(5):963–969.
  91. Inoh A, Kamiya K, Fujii Y, Yokoro K. Protective effects of progesterone and tamoxifen in estrogen induced mammary carcinogenesis in ovariectomized W/Fu rats. Jpn J Cancer Res. 1985;76(8):699–704.
  92. Peck JD, Hulka BS, Poole C, Savitz DA, Baird D, Richardson BE. Steroid hormone levels during pregnancy and incidence of maternal breast cancer. Cancer Epidemiol Biomarkers Prev. 2002;11(4):361–368.
  93. Micheli A, Muti P, Secreto G, et al. Endogenous sex hormones and subsequent breast cancer in premenopausal women. Int J Cancer. 2004;112(2):312–318.
  94. Bernstein L, Yuan JM, Ross RK, et al. Serum hormone levels in pre-menopausal Chinese women in Shanghai and white women in Los Angeles: results from two breast cancer case control studies. Cancer Causes Control. 1990;1(1):51–58.
  95. Drafta D, Schindler AE, Milcu SM, et al. Plasma hormones in pre- and postmenopausal breast cancer. J Steroid Biochem. 1980;13(7):793–802.
  96. Malarkey WB, Schroeder LL, Stevens VC, James AG, Lanese RR. Twenty-four-hour preoperative endocrine profiles in women with benign and malignant breast disease. Cancer Res. 1977;37(12):4655–4659.
  97. Meyer F, Brown JB, Morrison AS, MacMahon B. Endogenous sex hormones, prolactin, and breast cancer in premenopausal women. J Natl Cancer Inst. 1986;77(3):613–616.
  98. Secreto G, Toniolo P, Berrino F, et al. Increased androgenic activity and breast cancer risk in premenopausal women. Cancer Res. 1984(12 pt 1); 44:5902–5905.
  99. Cowan LD, Gordis L, Tonascia JA, Jones GS. Breast cancer incidence in women with a history of progesterone deficiency. Am J Epidemiol.1981;114(2):209–217.
  100. 1Badwe RA, Wang DY, Gregory WM, et al. Serum progesterone at the time of surgery and survival in women with premenopausal operable breast cancer. Eur J Cancer. 1994;30A(4):445–448.
  101. Mohr PE, Wang DY, Gregory WM, Richards MA, Fentiman IS. Serum progesterone and prognosis in operable breast cancer. Br J Cancer. 1996;73(12):1552–1555.
  102. Ory K, Lebeau J, Levalois C, et al. Apoptosis inhibition mediated by medroxyprogesterone acetate treatment of breast cancer cell lines.Breast Cancer Res Treat. 2001;68(3):187–198.
  103. Hofseth LJ, Raafat AM, Osuch JR, Pathak DR, Slomski CA, Haslam SZ. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab.1999;84(12):4559–4565.
  104. Jeng MH, Parker CJ, Jordan VC. Estrogenic potential of progestins in oral contraceptives to stimulate human breast cancer cell proliferation.Cancer Res. 1992;52(23):6539–6546.
  105. Kalkhoven E, Kwakkenbos-Isbrücker L, de Laat SW, van der Saag PT, van der Burg B. Synthetic progestins induce proliferation of breast tumor cell lines via the progesterone or estrogen receptor. Mol Cell Endocrinol. 1994;102(1–2):45–52.
  106. Papa V, Reese CC, Brunetti A, Vigneri R, Siiteri PK, Goldfine ID. Progestins increase insulin receptor content and insulin stimulation of growth in human breast carcinoma cells. Cancer Res.1990;50(24):7858–7862.
  107. Hissom JR, Moore MR. Progestin effects on growth in the human breast cancer cell line T-47D—possible therapeutic implications. Biochem Biophys Res Commun. 1987;145(2):706–711.
  108. Catherino WH, Jeng MH, Jordan VC. Norgestrel and gestodene stimulate breast cancer cell growth through an oestrogen receptor mediated mechanism. Br J Cancer. 1993;67(5):945–952.
  109. Schindler A: European Progestin Club. Differential effects of progestins. Maturitas 2003;46: S3-S5
  110. Wood CE, Register TC, Lees CJ, Chen H, Kimrey S, Cline JM. Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys. Breast Cancer Res Treat. 2007;101(2):125–134. 5
  111. Cline JM, Soderqvist G, von Schoultz E, Skoog L, von Schoultz B. Effects of conjugated estrogens, medroxyprogesterone acetate, and tamoxifen on the mammary glands of macaques. Breast Cancer Res Treat. 1998;48(3):221–229.
  112. Cline JM, Soderqvist G, von Schoultz E, Skoog L, von Schoultz B. Effects of hormone replacement therapy on the mammary gland of surgically postmenopausal cynomolgus macaques. Am J Obstet Gynecol. 1996;174(1 pt 1):93–100.
  113. Braunsberg H, Coldham NG, Wong W. Hormonal therapies for breast cancer: can progestogens stimulate growth? Cancer Lett. 1986;30(2):213–218.
  114. van der Burg B, Kalkhoven E, Isbrücker L, de Laat SW. Effects of progestins on the proliferation of estrogendependent human breast cancer cells under growth factor-defined conditions. J Steroid Biochem Mol Biol. 1992;42(5):457–465.
  115. Saitoh M, Ohmichi M, Takahashi K, et al. Medroxyprogesterone acetate induces cell proliferation through upregulation of cyclin D1 expression via phosphatidylinositol 3-kinase/Akt/nuclear factor-kappaB cascade in human breast cancer cells. Endocrinology. 2005;146(11):4917–4925.
  116. Birrell SN, Butler LM, Harris JM, et al. Disruption of androgen receptor signaling by synthetic progestins may increases risk of developing breast cancer. FASEB J. 2007 Aug;21(10):2285-93. Epub 2007 Apr 5.
  117. Seeger H, Mueck AO, Lippert TH. Effect of norethisterone acetate on estrogen metabolism in postmenopausal women. Horm Metab Res.2000;32(10):436–439.
  118. Coldham NG, James VH. A possible mechanism for increased breast cell proliferation by progestins through increased reductive 17 beta-hydroxysteroid dehydrogenase activity. Int J Cancer. 1990;45(1):174–178.
  119. Xu B, Kitawaki J, Koshiba H, et al. Differential effects of progestogens,by type and regimen, on estrogenmetabolizing enzymes in human breast cancer cells. Maturitas. 2007;56(2):142–152.
  120. Prost-Avallet O, Oursin J, Adessi GL. In vitro effect of synthetic progestogens on estrone sulfatase activity in human breast carcinoma.J Steroid Biochem Mol Biol. 1991;39(6):967–973.
  121. Pasqualini JR. Differential effects of progestins on breast tissue enzymes. Maturitas. 2003;46:45–54.
  122. Colditz GA, Hankinson SE, The Nurses’ Health Study: lifestyle and health among women. Nat Rev Cancer 2005 May;5(5):388-396.
  123. Schindler A: European Progestin Club. Differential effects of progestins. Maturitas 2003;46: S3-S5 Citation
  124. Barrat J, de Lignieres B, Marpeau L, et al. Effect in vivo de l’adminstration locale de progesterone sur l’activite mitotique des glaactorphores humains. [The in vivo effect of the local administration of progesterone on the mitotic activity of human ductal breast tissue. Results of a pilot study.] J Gynecol Obstet Biol Reprod (Paris). 1990;19(3):269–274.
  125. Malet C, Spritzer P, Guillaumin D, Kuttenn F. Progesterone effect on cell growth, ultrastructural aspect and estradiol receptors of normal breast epithelial (HBE) cells in culture. J Steroid Biochem Mol Biol. 2000;73(3–4):171–181.
  126. Mauvais-Jarvis P, Kuttenn F, Gompel A. Antiestrogen action of progesterone in breast tissue. Breast Cancer Res Treat. 1986;8(3):179–188.
  127. Soderqvist G, von Schoultz B, Tani E, Skoog L. Estrogen and progesterone receptor content in breast epithelial cells from healthy women during the menstrual cycle. Am J Obstet Gynecol. 1993;168(3 pt 1):874–879.
  128. Formby B, Wiley TS. Progesterone inhibits growth and induces apoptosis in breast cancer cells: inverse effects on Bcl-2 and p53. Ann Clin Lab Sci. 1998;28(6):360–369.
  129. Formby B, Wiley TS. Bcl-2, survivin and variant CD44 v7–v10 are downregulated and p53 is upregulated in breast cancer cells by progesterone:inhibition of cell growth and induction of apoptosis. Mol Cell Biochem. 1999;202(1–2):53–61.
  130. Groshong SD, Owen GI, Grimison B, et al. Biphasic regulation of breast cancer cell growth by progesterone: role of the cyclin dependent kinase inhibitors, p21 and p27(Kip1). Mol Endocrinol. 1997;11(11):1593–1607.
  131. Schmidt M, Renner C, Löffler G. Progesterone inhibits glucocorticoiddependent aromatase induction in human adipose fibroblasts. J Endocrinol.1998;158(3):401–407.
  132. Pollow K, Boquoi E, Baumann J, Schmidt-Gollwitzer M, Pollow B.Comparison of the in vitro conversion of estradiol-17 beta to estrone of normal and neoplastic human breast. Mol Cell Endocrinol. 1977;6(4–5):333–348.
  133. Fournier S, Kuttenn F, de Cicco F, Baudot N, Malet C, Mauvais-Jarvis P. Estradiol 17 beta-hydroxysteroid dehydrogenase activity in human breast fibroadenomas. J Clin Endo Metab. 1982;55(3):428–433.
  134. Segaloff A. Inhibition by progesterone of radiation-estrogen-induced mammary cancer in the rat. Cancer Res. 1973;33(5):1136–1137.
  135. Gottardis M, Ertürk E, Rose DP. Effects of progesterone administration on N-nitrosomethylurea-induced rat mammary carcinogenesis. Eur J Cancer Clin Oncol. 1983;19(10):1479–1484.
  136. Grubbs CJ, Farnell DR, Hill DL, McDonough KC. Chemoprevention of N-nitroso-N-methylurea induced mammary cancers by pretreatment with 17 beta-estradiol and progesterone. J Natl Cancer Inst. 1985;74(4):927– 931. 6
  137. Kledzik GS, Bradley CJ, Meites J. Reduction of carcinogen-induced mammary cancer incidence in rats by early treatment with hormones or drugs. Cancer Res, 1974;34(11):2953–2956.
  138. Welsch CH, Clemens JA, Meites J. Effects of multiple pituitary homografts or progesterone on 7,12- dimethylbenz[a]anthracene-induced mammary tumors in rats. J Natl Cancer Inst. 1968;41(2):465–478.
  139. Stanczyk F. All progestins are not created equal. Steroids 2003;68:879-890
  140. Pinto S, Virdis A, Ghiadoni L, et al. Endogenous estrogen and acetylcholine-induced vasodilation in normotensive women. Hypertension 1997;29:268-173.
  141. Virdis A, Ghiadoni L, et al. Mechanisms responsible for endothelial dysfunction associated with acute estrogendeprivation in normotensive women. Circulation 2000;101:2258-2263.
  142. Williams JK, Adams, MR, et al. Short-term administration of estrogen and vascular responses of atherosclerotic cornonary arteries. J Am Coll Cardiol 1992;20:452-457.
  143. 143. Guetta V, et al. The role of nitric oxide in coronary vascular effects of estrogen in postmenopausal women Circulation 1997;96:2795-2801.
  144. John S, Schmeider RE. Impaired endothelial function in arterial hypertension and hypercholesterolemia: potential mechanisms and differences. J Hyperten 200;18:363-374.
  145. 145. Cushman M, Kuller LH, Prentice R, et al. Estrogen plus progestin and risk of venous thrombosis. JAMA. 2004;292(13):1573–1580.
  146. Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007;115(7):840–845
  147. Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, Taisne P, Agher R, Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. Arterioscler Thromb Vasc Biol.1997;17(11):3071–3078.
  148. Martinez C, Basurto L, Zarate A, Saucedo R, Gaminio E, Collazo J. Transdermal estradiol does not impair hemostatic biomarkers in postmenopausal women. Maturitas. 2005;50(1):39–43.
  149. Oger E, Alhenc-Gelas M, Lacut K, et al. Differential effects of oral and transdermal estrogen/progesterone
  150. regimens on sensitivity to activated protein C among postmenopausal women: a randomized trial. Arterioscler Thromb Vasc Biol. 2003;23(9):1671–1676.
  151. 150. Gebhard M., Walsh BW, et al. Estradiol therapy combined with progesterone and endothelium-dependent vasodilation in postmenopausal women. Circulation 1998;98:1158-1163. Stephenson K, et al. Transdermal estradiol and progesterone improve mood indicators, quailty of life, and biomarkers of cardiovscular disease in perimenopausal and postmenopausal women. Circulation 2007;115(8) http://circ.ahajournals.org
  152. Stephenson K et al. Topical progesterone cream does not increase thrombotic and inflammatory factors in postmenopausal women. Boood 2004:104(11):414b-415b.
  153. Feeman WE Jr. Thrombotic stroke in an otherwise healthy middle aged female related to the use of continuous-combined conjugated equine estrogens and medroxyprogesterone acetate. J Gend Specif Med. 2000;3(8):62–64.
  154. Cole JA, Norman H, Doherty M, Walker AM. Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users. Obstet Gynecol. 2007;109(2 pt 1):339–346.
  155. Jick SS, Kaye JA, Russmann S, Jick H. Risk of nonfatal venous thromboembolism in women using acontraceptive transdermal patch and oral contraceptives contain norgestimate and 35 μg of ethinyl estradiol. Contraception. 2006;73(3):223–228.
  156. HERS Study report: HT can relieve menopause-type symptoms common in elderly women. ACOG News release. 2002
  157. Hodis HN, St John JA, Xiang M, Cushman M, Lobo RA, Mack WJ. Inflammatory markers and progression of subclinical atherosclerosis in healthy postmenopausal women (from the Estrogen in the Prevention of Atherosclerosis Trial). Am J Cardiol. 2008 Apr 15;101(8):1131-3. Epub 2008 Feb 14
  158. Ottosson UB, Johansson BG, von Schoultz B. Subfractions of high-density lipoprotein cholesterol during estrogen replacement therapy: a comparison between progestogens and natural progesterone.Am J Obstet Gynecol. 1985;151(6):746–750.
  159. Minshall RD, Stanczyk FZ, Miyagawa K, et al. Ovarian steroid protection against coronary artery hyperreactivity in rhesus monkeys. J Clin Endocrinol Metab. 1998;83(2):649–659.
  160. Mishra RG, Hermsmeyer RK, Miyagawas K, et al. Medroxyprogesterone acetate and dihydrotestosterone induce coronary hyperreactivity in intact male rhesus monkeys. J Clin Endocrinol Metab. 2005;90(6):3706–3714.
  161. Miyagawa K, Roöch J, Stanczyk F, Hermsmeyer K. Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm. Nat Med. 1997;3(3):324–327. 7
  162. Adams MR, Register TC, Golden DL, Wagner JD, Williams J. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler Thromb Vasc Biol. 1997;17(1):217–221.
  163. Saarikoski S, Yliskoski M, Penttilä I. Sequential use of norethisterone and natural progesterone in premenopausal bleeding disorders.Maturitas. 1990;12(2):89–97.
  164. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA. 1995;273(3):199–208.
  165. Fåhraeus L, Larsson-Cohn U, Wallentin L. L-norgestrel and progesterone have different influences on plasma lipoproteins. Eur J Clin Invest. 1983;13(6):447–453.
  166. Larsson-Cohn U, Fåhraeus L, Wallentin L, Zador G. Lipoprotein changes may be minimized by proper composition of a combined oral contraceptive. Fertil Steril. 1981;35(2):172–179.
  167. Ottosson UB. Oral progesterone and estrogen/progestogen therapy. Effects of natural and synthetic hormones on subfractions of HDL cholesterol and liver proteins. Acta Obstet Gynecol Scand Suppl. 1984;127:1–37.
  168. Mälkönen M, Manninen V, Hirvonen E. Effects of danazol and lynestrenol on serum lipoproteins in endometriosis. Clin Pharmacol Ther. 1980;28(5):602–604.
  169. 169. Hirvonen E, Malkonen M, Manninen V. Effects of different progestogens on lipoproteins during postmenopausal replacement therapy.N Engl J Med. 1981;304(10):560–563.
  170. Cushman M, Kuller LH, Prentice R, et al. Estrogen plus progestin and risk of venous thrombosis. JAMA. 2004;292(13):1573–1580.
  171. Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007;115(7):840–845.
  172. Rosano GM, Webb CM, Chierchia S, et al. Natural progesterone, but not medroxyprogesterone acetate, enhances the beneficial effect of estrogen on exercise-induced myocardial ischemia in postmenopausal women. J Am Coll Cardiol. 2000;36(7):2154–2159.
  173. Miller VT, Muesing RA, LaRosa JC, Stoy DB, Phillips EA, Stillman RJ. Effects of conjugated equine estrogen with and without three different progestogens on lipoproteins, high-density lipoprotein subfractions, and apolipoprotein A-1. Obstet Gynecol. 1991;77(2):235–240.
  174. Levine RL, Chen SJ, Durand J, Chen YF, Oparil S. Medroxyprogesterone attenuates estrogen-mediated inhibition of neointima formation after balloon injury of the rat carotid artery. Circulation.1996;94(9):2221–2227.
  175. Otsuki M, Saito H, Xu X, et al. Progesterone, but not medroxyprogesterone, inhibits vascular cell adhesion molecule-1 expression in human vascular endothelial cells. Arterioscler Thromb Vasc Biol 2001;21(2):243–248.
  176. Register TC, Adams MR, Golden DL, Clarkson TB. Conjugated equine estrogens alone, but not in combination with medroxyprogesterone acetate, inhibit aortic connective tissue remodeling after plasma lipid lowering in female monkeys. Arterioscler Thromb Vasc Biol. 1998;18(7):1164–1171.
  177. Wagner JD, Martino MA, Jayo MJ, Anthony MS, Clarkson TB, Cefalu WT. The effects of hormone replacement therapy on carbohydrate metabolism and cardiovascular risk factors in surgically postmenopausal cynomolgus monkeys. Metabolism. 1996;45(10):1254–1262.
  178. Lindheim SR, Presser SC, Ditkoff EC, Vijod MA, Stanczyk FZ, Lobo RA. A possible bimodal effect of estrogen on insulin sensitivity in postmenopausal women and the attenuating effect of added progestin. Fertil Steril. 1993;60(4):664–667.
  179. Spencer CP, Godsland IF, Cooper AJ, Ross D, Whitehead MI, Stevenson JC. Effects of oral and transdermal 17β-estradiol with cyclical oral norethindrone acetate on insulin sensitivity, secretion, and elimination in postmenopausal women. Metabolism.2000;49(6):742–747.
  180. Godsland IF, Gangar K, Walton C, et al. Insulin resistance, secretion, and elimination in postmenopausal women receiving oral or transdermal hormone replacement therapy. Metabolism.1993;42(7):846–853.
  181. Feeman WE Jr. Thrombotic stroke in an otherwise healthy middleaged female related to the use of continuous-combined conjugated equine estrogens and medroxyprogesterone acetate. J Gend Specif Med. 2000;3(8):62–64.
  182. Jeanes HL, Wanikiat P, Sharif I, Gray GA. Medroxyprogesterone acetate inhibits the cardioprotective effect of estrogen in experimental ischemia-reperfusion injury. Menopause. 2006;13(1):80–86.
  183. Hermsmeyer RK, Thompson TL, Pohost GM, Kaski JC. Cardiovascular effects of medroxyprogesterone acetate and progesterone: a case of mistaken identity? Nat Clin Pract Cardiovasc Med. 2008 Jul;5(7):387-95.
  184. Koh KK, et al. Vascular effects of synthetic or natural progestagen combined with conjugated equine estrogen in healthy postmenopasaul women. Circulation 2001;103:1961-1966
  185. 185. Jensen J, Riis BJ, Strøm V, Nilas L, Christiansen C. Long-term effects of percutaneous estrogens and oral progesterone on serum lipoproteins in postmenopausal women. Am J Obstet Gynecol. 1987;156(1):66–71. 8
  186. Williams JK, Honoré EK, Washburn SA, Clarkson TB. Effects of hormone replacement on therapy on reactivity of atherosclerotic coronary arteries in cynomolgus monkeys. J Am Coll Cardiol.1994;24(7):1757–1761.
  187. Adams MR, Kaplan JR, Manuck SB, et al. Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys. Lack of an effect of added progesterone. Arteriosclerosis.1990;10(6):1051–1057.
  188. Bolaji II, Grimes H, Mortimer G, Tallon DF, Fottrell PF, O’Dwyer EM. Low-dose progesterone therapy in oestrogenised postmenopausal women: effects on plasma lipids, lipoproteins and liver function parameters. Eur J Obstet Gynecol Reprod Biol. 1993;48(1):61–68.
  189. Morey AK, Pedram A, Razandi M, et al. Estrogen and progesterone inhibit vascular smooth muscle proliferation. Endocrinology. 1997;138(8):3330–3339.
  190. Lee WS, Harder JA, Yoshizumi M, Lee ME, Haber E. Progesterone inhibits arterial smooth muscle cell proliferation. Nat Med.1997;3(9):1005–1008.
  191. Holtorf K. The Bioidentical Hormone Debate: Are Bioidentical Hormones (Estradiol, Estriol, and Progesterone) Safer or More Efficacious than Commonly Used Synthetic Versions in Hormone Replacement Therapy? Postgraduate Medicine 2009; 121(1) ISSN-0032-5481.
  192. Minshall RD, Miyagawa K, Chadwick CC, Novy MJ, Hermsmeyer K. In vitro modulation of primate coronary vascular muscle cell reactivity by ovarian steroid hormones. FASEB J. 1998;12(13):1419–1429.
  193. Minshall RD, Pavcnik D, Halushka PV, Hermsmeyer RK. Progesterone regulation of vascular thromboxane A2 receptors in rhesus monkeys. Am J Physiol Heart Circ Physiol. 2001;281(4):H1498–H1507
  194. Hermsmeyer RK, Mishra RG, et al. Prevention of coronary hyperactivity in pre-atherogenic menopasusal rhesus monkeys by transdermal progesterone. Arteriosclerosis Thromb Vasc Biol 2004;24:955-961.
  195. Corvol P, Elkik F, Feneant M, et al. Effect of progesterone and progestins on water and salt metabolism. In: Bardin CW, Milgrom E, Mauvais-Jarvis P, eds. Progesterone and Progestins. New York, NY:Raven Press; 1983;1979–1986.
  196. Rylance PB, Brincat M, Lafferty K, et al. Natural progesterone and antihypertensive action. Bri Med J. 1985(6461);290:13–14.
  197. Elkind-Hirsch KE, Sherman LD, Malinak R. Hormone replacement therapy alters insulin sensitivity in young women with premature ovarian failure. J Clin Endocrinol Metab. 1993;76(2):472–475.
  198. Fitzpatrick LA, Pace C, Witta B. Comparison of regimens containing oral micronized progesterone or medroxyprogesterone acetate on quality of life in postmenopausal women: a cross-sectional survey. J Womens Health Gend Based Med 2000;9(4):382-387.
  199. Cummings Ja, Brizendine L. Comparison of physical and emotional side effects of progesterone or medroxyprogesterone acetate in early postmenopausual women. Menopause. 2002;9:253-263
  200. Lindenfeld EA, Langer RD. Bleeding patterns of the hormone replacement therapies in the postmenopausal estrogen and progestin interventions trial. Obstet Gynecol 2002;100(5 pt 1):853-863.
  201. Greendale GA, Reboussin BA, Hogan P, et al. Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Estrogen/Progestin Interventions Trial. Obstet Gynecol 1998;92(6):982-988.
  202. Ojasoo, T. et al. Affiliations Among Steroid Receptors as Revealed by Multivariate Analysis of Steroid Binding Data.J. Steroid Biochem. Molec. Biol., Vol. 48, No. 1, pp. 31-46, 1994
  203. Physicians Desk Reference, 44th edition, 1990
  204. Hellman I, Yoshida K, Zumoff B, Levin J, Kream J, Fukushima DK. The effect of medroxyprogesterone acetate on the pituitary-adrenal axis. J Clin Endocrinol Metab. 1976;42(5):912–917.
  205. Davila E, Vogel CL, East D, Cairns V, Hilsenbeck S. Clinical trial of high-dose oral medroxyprogesteorne acetate in the treatment of metastatic breast cancer and review of the literature. Cancer. 1988;61(11):2161–2167.
  206. Sammour MB, et.al. Progesterone therapy in preclamptic toxaemia. Acta Obstet Gynec Scand. 1975; 54: 195-202.
  207. Sammour MB, et.al. Progesterone thjerapy in pregnancy-induced hypertension therapeutic value and hormonal profile. Clin & Exp Hyper-Hyper in Preg. 1982; B1:455-78.
  208. The Use of Estrogens and Progestogens in Clinical Practice. Edited by Fraer I, Janses R, Lobo R, WhiteheadM. Jan 1999 Churchhill Livingston
  209. Darj E, et al. Liver metabolism during treatment with estradiol and natural progesterone. Gynecol Ednocrinol1993 (7) 111-114.
  210. Montplaisir J, et al.. Sleep in menopause: differential effects of two forms of hormone replacement therapy.Menopause 2001 Jan/Feb; 8)1):1016
  211. Arafat, ES, et al. Sedative and hypnotic effects of oral administration of micronized progesterone may bemediated through its metabolites. Am J Obstet Gynecol Nov 1988;159(6):1203-1209.
  212. Morrell MJ. Epilepsy in Women Am Fam Physician 2002; 66(8):1489-94.
  213. Schwartz ET, Holtorf K. Hormones in Wellness and Disease Prevention: Common Practices, Current State of the Evidence, and Questions for the Future. Prim Care 2008 Dec;35(4):669-705. 9
  214. Seifer DB, Speroff L. Clinical Gynecologic Endocrinology and Infertility, 7th Edition. 2004. Lippincott Williams& Wilkins (LWW)
  215. Grow DR. Metabolism of endogenous and exogenous reproductive hormones Obstet Gynecol Clin North Am. 2002 Sep;29(3):425-36.
  216. Shapiro S. Addressing postmenopausal estrogen deficiency: a position paper of the American Council on Science and Health. MedGenMed. 2001 Jan 26:E7.
  217. Greenblatt RB, Natrajan PK, Aksu MF, Tzingounis VA. The fate of a large bolus of exogenous estrogen administered to postmenopausal women. Maturitas. 1980 Jan;2(1):29-35
  218. Friel PN, Hinchcliffe C, Wright JV. Hormone replacement with estradiol: conventional oral doses result in excessive exposure to estrone. Altern Med Rev. 2005 Mar;10(1):36-41.
  219. Stanzyck FZ, Paulson RJ, Roy S. Percutaneous administration of progesterone: blood levels and endometrial protection. Menopause. 2005 Mar;12(2):232-7.
  220. De Boever J, Verheugen C Van Maele G, Vandekerckhove D. Steroid concentrations in serum, glandular breast tissue, and breast cyst fluid of control and progesterone-treated patients. Endocrinology of Cystic Breast Disease, ed. A.Angeli, Raven Press, New York, 1983; 93-99.
  221. Leonetti HB, Landes J, Steinberg D, Anasti JN. Topical progesterone cream as an alternative progestin in hormone therapy. Altern Ther Health Med 2005; 11(6):36-38.
  222. Chang K-J, Lee TTY, Linares-Cruz G, Fournier S, de Lignieres B. Influences of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo. Fertility and Sterility 1995;63:785-791.
  223. Waddell BJ, O’Leary PC. Distribution and metabolism of topically applied progesterone in a rat model. J Steroid Biochemistry & Molecular Biology 2002; 80; 449-455.
  224. Sitruk-Ware R, Sterkers N, Mowszowicz I, Mauvais-Javis P. Inadequate corpus luteum function in women with benign breast diseases. J. Clin. Endocrinol. Metabol. 1977: 44: 771-774.
  225. Johnson ME, et al. Permeation of steroids through human skin. J Pharmaceutical Sci 84: 1144-1146, 1995.
  226. Burry KA, Patton PE, Hermsmeyer K. Percutaneous absorption of progesterone in postmenopausal women treated with transdermal estrogen. Am J Obstet Gynecol. 1999;180(6 pt 1):1504-1511.
  227. Dollbaum CM, Duwe GF. Absorption of progesterone after topical applications: serum and saliva levels. Presented at the 7th Annual Meeting of the American Menopause Society. Reprinted with permission, 2009

Our new office is conveniently located in the heart of beautiful South Glastonbury, CT. ( click here for directions)

Asthma • Fatigue • Insomnia • Colitis & Crohn’s • Fibromyalgia • Migraines • Depression • Heart Disease
• Osteoporosis • Diabetes • Inflammation • Sleep Disorders
MONACO CENTER FOR HEALTH & HEALING LLC, 1015 Main Street, South Glastonbury, CT. 06073, P: 860-657-3512 F: 860-657-3516
Medical Disclaimer: All information on this site is of a general nature and is furnished for your knowledge and understanding only. This information is not to be taken as medical or other health advice pertaining to your specific health and medical condition. Glastonbury Doctor John B. Monaco specializes in natural hormone replacement for men and woman. Dr. Monaco provides personalized, comprehensive, state-of-the-art medical care to help you look years younger. The Monaco Center for Health & Healing takes a "whole life" view of your care – hormone balancing for men and woman, nutrition, supplements, exercise, massage therapy and Reiki stress reduction. Avoid premature aging, reach and maintain your ideal weight, increase your energy level and focus, eat nutritiously, fight, manage and prevent common and chronic illnesses: Asthama, Fatigue, Insomnia, Colitis, Crohn's, Fibromyalgia, Migraines, Depression, Heart Disease, Oseoporosis, Diabetes, Inflammation and Sleep Disorders. The Monaco Center services patients in: Avon, Grandby, East Granby, Simsbury, Windsor, Bloomfield, East Hartford, Hartford, South Windsor, Vernon, Manchester, Bolton, Glastonbury, Hebron, Marlborough, East Hampton, East Haddam, Haddam, Middletown, Durham, Middlefield, Meriden, Cromwell, Rocky Hill, Berlin, New Britain, Wethersfield, Farmington, Burlington, Bristol, Plainville, Wallingford, North Branford, Killingworth, Deep River, Chester and more.
worldhealth.net – zrtlab.com – beaconcompounding.com – healthtrax.com – hartfordcosmeticdentist.com – glastonburychiro.com – quantumenergetics –

Home l Whole Life Medicine l Our Vision of Your Health l Patient Education l Forms l Testimonials l Contact/Directions l Shop: Medical Grade Products l About Dr. Monaco l Coming Events l Meet our Staff l Asthma l Natural Hormones l Colitis & Crohn's l Depression l Diabetes l Fatigue l Fibromyalgia l Heart Disease l Inflammation l Insomnia l Migraine Therapy l Osteoporosis l Sleep Disorder l Vitamin D l Human Growth Hormone l Thyroid l DHEA l Estradiol l Testosterone l Progesterone l Insulin l Men, Hormone Therapy l Men, Body Building l Men, Cosmetic Services l Men, Diabetes & Obesity l Men, Heart Disease l Men, Libido & Depression l Sexual Performance l Women, Hormone Therapy l Women, Chronic Pelvic Pain l Women, Cosmetic Services l Women, Diabetes & Obesity l Women, Endometriosis l Women, Menstrual Pain l Women, Menopause l Women, Migraine & Back Pain l Women, P.M.S. & Depression l Women, Polycystic Ovaries l Women, Sex Drive l Women, Vaginitis l Aqua Detox l Nutritional Supplements l Weight Loss l Botox l Laser Skin Peel l Filler-Restylane l Hair & Vein l Liquid Facelift l Evidence Based Medicine l Anti-Aging Cosmeceuticals l Aesthetics l Detoxify and Cleanse l Pharmacies & ZRT Labs l Literature/Books l Sitemap